Joseph Alvarnas, MD: Understanding, in light of what you’ve all said, that cancer care is multidimensional and value is multidimensional, have value frameworks—such as those developed by the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), or the Institute for Clinical and Economic Review (ICER)—been adopted into practice in a way that you think changes the industry? And if so, how do you think they influence patient care? Bob, do you think we’re getting to more patient-centered care through these frameworks?
Robert Carlson, MD: I think the frameworks have different goals and different purposes. ICER is a framework that is really designed to understand what optimal drug pricing should be. And that really faces the payer community, the pharmaceutical industry, and the device industry rather than the patients and physicians. The ASCO Value Framework and the NCCN Evidence Blocks are really designed to focus on the physicians and the patients. The ASCO system is not yet, to my understanding, utilized in clinics, although ASCO is developing computer-based systems to allow that to happen. In terms of the NCCN Evidence Blocks, we currently have 33 guidelines with evidence blocks associated with them. We have limited that to the professional guidelines because we want the physician community to become comfortable with them before it’s expanded to patients so that—when a patient comes in and asks about them—the physician knows what they’re talking about.
But we are also working with patient advocacy groups because we also need tools that are patient centric and optimally developed by patients that can interface with the professional tools and are value-oriented tools. Because both the professional audience and the patient audience have very different needs in terms of what a value tool looks like. They should come up with, optimally or ultimately, the same sort of spectrum of options, but how we get there is a very different process, and we need processes for getting to values that are meaningful to patients.
As an oncologist, survival is valuable to me. Avoidance of toxicity is valuable to me. If we go to the patient community and ask, “What is valuable to you?” you hear about things like free parking. You hear, “The most valuable thing to me is my personal relationship with my medical oncologist.” Those are the sorts of things that you hear about, and they’re not necessarily mutually exclusive, but there’s a hugely different emphasis on the types of things that are sought.
John Fox, MD: I think these tools are on version 1.0 or 1.1 right now. I think the ASCO Value Framework has recognition, or values, treatment-free intervals, and patient-reported outcomes. Although, interestingly, I think it was FARYDAK (panobinostat), which is used to treat multiple myeloma, that got points because it was so toxic that patients had to stop taking it—and so they got a treatment-free interval. So, there are some nuances to that. I don’t think the NCCN Evidence Blocks take into account any of those things today, but I think they’ll continue to evolve. I think the challenge from the payer vantage point right now—I use them. I look at them frequently, more to assess whether or not the decisions that we’re making as a health plan are concordant or discordant with the evidence blocks or the value frameworks. But I think we’re probably a long way from using those as a fundamental element or an integral element of formulary decision making today.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More